Logo Logo
Help
Contact
Switch Language to German
Costabel, Ulrich; Behr, Jürgen; Crestani, Bruno; Stansen, Wibke; Schlenker-Herceg, Rozsa; Stowasser, Susanne; Raghu, Ganesh (2018): Anti-acid therapy in idiopathic pulmonary fibrosis: insights from the INPULSIS (R) trials. In: Respiratory Research 19:167
[img]
Preview
761kB

Abstract

Background: The benefits and risks of anti-acid medication in patients with idiopathic pulmonary fibrosis (IPF) remain a topic of debate. We investigated whether use of anti-acid medication at baseline was associated with differences in the natural course of disease or influenced the treatment effect of nintedanib in patients with IPF. Methods: Post-hoc analyses of outcomes in patients receiving versus not receiving anti-acid medication (proton pump or histamine-2 receptor inhibitor) at baseline using pooled data from the two Phase III randomized placebo-controlled INPULSIS (R) trials of nintedanib in patients with IPF. Results: At baseline, 406 patients were receiving anti-acid medication (244 nintedanib;162 placebo) and 655 were not (394 nintedanib;261 placebo). In an analysis of the natural course of IPF by anti-acid medication use at baseline, the adjusted annual rate of decline in FVC was -252.9 mL/year in placebo-treated patients who were receiving anti-acid medication at baseline and -205.4 mL/year in placebo-treated patients who were not (difference of -47.5 mL/year [95% CI: -105.1, 10.1];p = 0.1057). In an analysis of the potential influence of anti-acid medication use on the treatment effect of nintedanib, the adjusted annual rates of decline in FVC were -124.4 mL/year in the nintedanib group and 252.9 mL/year in the placebo group (difference of 128.6 mL/year [95% CI: 74.9, 182.2]) in patients who were receiving anti-acid medication at baseline and -107.0 mL/year in the nintedanib group and -205.3 mL/year in the placebo group (difference of 98.3 mL/year [95% CI: 54.1, 142.5]) in patients who were not (treatment-by-time-by-subgroup interaction p = 0.3869). The proportions of patients who had >= 1 investigator-reported acute exacerbation were 11.7% and 5.0% in placebo-treated patients, and 4.9% and 4.8% of nintedanib-treated patients, among patients who were and were not receiving anti-acid medication at baseline, respectively. Conclusions: In post-hoc analyses of data from the INPULSIS (R) trials, anti-acid medication use at baseline was not associated with a more favorable course of disease, and did not impact the treatment effect of nintedanib, in patients with IPF.